06127.HK
JOINN Laboratories (China) Co., Ltd.
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 22.74
−3.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.7B | 2.0B | 2.4B | 2.3B |
| Cost of Revenue | 1.4B | 1.3B | 1.4B | 1.4B | 1.2B |
| Gross Profit | 340.4M | 343.3M | 573.8M | 1.0B | 1.1B |
| Operating Expenses | |||||
| R&D Expense | 84.7M | 87.4M | 92.9M | 96.9M | 78.0M |
| SG&A Expense | 118.0M | 120.1M | 118.7M | 100.8M | 96.4M |
| General & Admin Expense | (44.9M) | 101.7M | 103.7M | 89.0M | 78.4M |
| Selling & Marketing Expense | 2.5M | 18.3M | 15.0M | 11.8M | 18.0M |
| Other Expenses | (275.3M) | (202.2M) | 257.8M | 308.0M | 194.7M |
| Total Operating Expenses | (72.6M) | 5.3M | 469.4M | 505.7M | 369.1M |
| Cost and Expenses | 1.3B | 1.3B | 1.9B | 1.9B | 1.6B |
| Operating Income (EBIT) | 413.1M | 338.0M | 104.3M | 507.1M | 1.2B |
| Non-Operating | |||||
| Interest Income | 81.6M | 78.2M | 103.2M | 142.5M | 131.2M |
| Interest Expense | 1.3M | 1.4M | 325.7K | 3.4M | 3.6M |
| Net Interest Income | 80.3M | 76.8M | 102.9M | 139.1M | 130.5M |
| Other Non-Op Income/Expense | 657.2M | (497.9K) | (308.2K) | (145.9K) | 14.4M |
| Non-Operating Income (excl Interest) | (81.0K) | (923.8K) | 308.2K | (2.9M) | (14.7M) |
| EBT (Pre-Tax Income) | 1.1B | 337.5M | 104.0M | 507.0M | 1.2B |
| Income Tax Expense | 88.0M | 39.7M | 34.3M | 115.4M | 166.8M |
| Bottom Line | |||||
| Net Income | 982.3M | 297.8M | 74.1M | 397.0M | 1.1B |
| Earnings from Cont. Ops | 982.3M | 297.8M | 69.8M | 391.6M | 1.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 982.3M | 297.8M | 74.1M | 397.0M | 1.1B |
| Per Share | |||||
| Basic EPS | HK$1.33 | HK$0.40 | HK$0.10 | HK$0.53 | HK$2.01 |
| Diluted EPS | HK$1.33 | HK$0.40 | HK$0.10 | HK$0.53 | HK$2.00 |
| Revenue Per Share | HK$2.31 | HK$2.23 | HK$2.69 | HK$3.17 | HK$4.22 |
| Shares | |||||
| Basic Shares Outstanding | 733.4M | 744.6M | 749.5M | 749.0M | 537.1M |
| Diluted Shares Outstanding | 733.4M | 744.6M | 749.5M | 749.0M | 537.1M |
| Profitability Metrics | |||||
| EBITDA | 450.8M | 483.2M | 234.4M | 639.5M | 1.4B |
| D&A | 131.4M | 144.3M | 130.3M | 129.5M | 121.0M |
| EBIT | 413.1M | 338.9M | 104.0M | 510.0M | 1.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026